Enjoy complimentary customisation on priority with our Enterprise License!
Lipodystrophy syndrome is a rare genetic disorder, which causes fat loss or abnormal distribution or accumulation of fat tissues in the body. The amount of fat loss can be determined by the severity of metabolic complications. Lipodystrophy syndrome causes several metabolic complications such as insulin resistance, diabetes mellitus, hepatic steatosis, and dyslipidemia. According to the National Institutes of Health (NIH), lipodystrophy is a rare disease. The familial partial lipodystrophy is estimated to be affecting one in a million people. Women are found to be more affected by familial partial lipodystrophy as compared with men. The growing instances of the lipodystrophy syndrome are expected to proliferate the drug development for lipodystrophy syndrome in the next few years.
According to our pipeline analysis report, most of the drug development molecules in the pipeline are under the phase II and pre-clinical stages. For instance, sponsors such as Ambrx developed ARX328 and Bolder BioTechnology developed BBT-031, which are in the pre-clinical stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under discovery, phase III, phase II/III stages, IND, and phase I.
Want a bigger picture? Try a FREE sample of this report now!
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of lipodystrophy syndrome. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
The oral route of administration (ROA) involves the administration of the drug through the mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration. The drug is administered through the mouth cavity.
According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for lipodystrophy syndrome are being developed as oligonucleotides. Oligonucleotides are polynucleotides whose molecules contain a relatively small number of nucleotides. They are synthesized to be used as a therapeutic agent by blocking the disease process through altering the synthesis of a particular protein.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.